Waverley Pharma Inc

NEW
STU:5GZ (Canada)  
€ 0.006 (0%) Dec 11
At Loss
Market Cap:
€ 362.00K ($ 380.00K)
Enterprise V:
€ 2.19M ($ 2.30M)
Volume:
-
Avg Vol (2M):
8.35K
Trade In:

Business Description

Description
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.08
Equity-to-Asset -1.13
Debt-to-Equity -1.47
Debt-to-EBITDA -1.63
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -16.56
Distress
Grey
Safe
Beneish M-Score -8.2
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 41.7
9-Day RSI 45.48
14-Day RSI 46.96
3-1 Month Momentum % -7.14
6-1 Month Momentum % -27.78
12-1 Month Momentum % -53.57

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.13
Quick Ratio 0.09
Cash Ratio 0.07
Days Inventory 117.58
Days Sales Outstanding 116.2
Days Payable 818.87

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % -224.85

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 20.71
Operating Margin % -573.37
Net Margin % -905.33
FCF Margin % -312.12
ROA % -217.95
ROIC % -68.66
3-Year ROIIC % -160.24
ROC (Joel Greenblatt) % -766.54

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.67
EV-to-EBIT -1.67
EV-to-EBITDA -1.8
EV-to-Revenue 9.66
EV-to-FCF -3.11
Price-to-GF-Value 0.6
Earnings Yield (Greenblatt) % -59.79
FCF Yield % -193.72

Financials

STU:5GZ's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Waverley Pharma Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.231
EPS (TTM) (€) -0.037
Beta 0.61
3-Year Sharpe Ratio -0.2
3-Year Sortino Ratio -0.31
Volatility % 107.36
14-Day RSI 46.96
14-Day ATR (€) 0.002586
20-Day SMA (€) 0.007
12-1 Month Momentum % -53.57
52-Week Range (€) 0.0035 - 0.0185
Shares Outstanding (Mil) 54

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Waverley Pharma Inc Filings

Filing Date Document Date Form
No Filing Data

Waverley Pharma Inc Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Waverley Pharma Inc Frequently Asked Questions

What is Waverley Pharma Inc(STU:5GZ)'s stock price today?
The current price of STU:5GZ is €0.01. The 52 week high of STU:5GZ is €0.02 and 52 week low is €0.00.
When is next earnings date of Waverley Pharma Inc(STU:5GZ)?
The next earnings date of Waverley Pharma Inc(STU:5GZ) is .
Does Waverley Pharma Inc(STU:5GZ) pay dividends? If so, how much?
Waverley Pharma Inc(STU:5GZ) does not pay dividend.

Press Release

Subject Date
No Press Release